Insmed-AstraZeneca negotiation for brensocatib in COPD/asthma expires without agreement

INSMED Inc

AstraZeneca exercised final option for brensocatib in COPD/asthma on March 8, 2024.
Negotiation period expired June 12, 2024; no agreement reached.
Insmed retains full worldwide rights to brensocatib outside COPD/asthma.
AstraZeneca has no further rights to develop or commercialize brensocatib in any indication.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.